ProQR Therapeutics N.V. PRQR
1.65
(0.06)
(3.51%)
as of 25 Sep
- Market cap
- $236.1M
- P/E
- 0.0×
Follow PRQR
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(100.28%) | (62.93%) | (83.00%) | (58.29%) | |
| (35.93%) | (30.86%) | (38.28%) | (31.53%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(44.29%) | (52.52%) | (70.48%) | (42.79%) | |
Average Days of Receivables |
0.00 | 156.04 | 120.49 | 77.26 | |
Free Cash Flow per Share |
(0.54) | (0.58) | (0.54) | (0.52) | |
Free Cash Flow |
(56.44) | (60.88) | (57.24) | (57.39) | |
Capital Expenditures |
(0.70) | (1.15) | (1.11) | (1.31) | |
Piotroski F-Score |
2.00 | 0.00 | 0.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(28.26%) | (36.00%) | (38.79%) | (23.92%) | |
Accounts Receivable Turnover |
0.00 | 0.52 | 5.53 | 8.62 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
294.06% | 281.23% | 329.65% | 248.08% | |
Selling, General and Administrative Expense of Revenue |
97.82% | 94.68% | 116.17% | 85.66% | |
Share Based Compensation of Revenue |
22.46% | 25.24% | 34.67% | 27.43% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.18 | 1.25 | 1.06 | 1.14 | |
Depreciation/Fixed assets |
0.20 | 0.21 | 0.22 | 0.23 | |
Capex/Depreciation |
(0.23) | (0.38) | (0.35) | (0.42) | |
Revenue per Share |
0.16 | 0.17 | 0.15 | 0.20 | |
Operating CF per Share |
(0.53) | (0.57) | (0.53) | (0.51) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.04 | 0.06 | 0.07 | 0.06 | |
Net Profit Margin |
(276.59%) | (265.21%) | (337.96%) | (228.71%) |
Columns are period end dates